Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07684144 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Name: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) — clinical trial record (NCT07684144)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2026-07-29

View on ClinicalTrials.gov ↗

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

Amendment history 3 changes detected by DataLookout

2026-08-28

Trial sites expanded: 24 → 37 locations

2026-08-25

Recruitment opened

2026-08-25

Trial sites expanded: 0 → 24 locations

Trial Details

NCT Number	NCT07684144
Lead Sponsor	Amgen
Conditions	Obesity, Overweight, Diabetes Mellitus, Type 2
Enrollment	950 participants
Start Date	2026-07-29
Primary Completion	2027-12-26 (estimated)
Study Completion	2028-03-19 (estimated)
Updated on ClinicalTrials.gov	2026-09-03